

**MINUTES OF FINANCIAL EVALUATION COMMITTEE MEETING FOR TENDER NO.-  
BMSIC/DRUGS/22-06 (SHORT RE-TENDER FOR RATE CONTRACT AND SUPPLY OF DRUGS  
FOR DIFFERENT HEALTHCARE FACILITIES OF STATE OF BIHAR).**

**Date: 31<sup>st</sup> May 2022**

**Venue: BMSICL Conference Hall.**

The **Financial Evaluation Committee Meeting for Tender No. BMSIC/DRUGS/22-06** was held on **31<sup>st</sup> May 2022** under the Chairmanship of **Managing Director, BMSICL**. The other committee members present in the meeting were:

1. Sh. Shrawan Kumar, Internal Financial Advisor (IFA), of Health Department, GoB.
2. Dr. Maheshwar Prasad Gupta, Director in Chief, Health Department, GoB.
3. Sh. Rajani Kant, CGM (Supply Chain), BMSICL.
4. Sh. Sudhir Kumar, GM (Procurement), BMSICL.
5. Dr. Vidyapati Choudhary, Principal PMCH, Patna.
6. Sh. Ramendra Kumar, GM (Finance), BMSICL.

**2. The Details of the invited tender are as follows:**

1. Tender Reference No. BMSIC/DRUGS/22-06.
2. Tender floated date- 19/04/2022.
3. Last date of submission of Online bids- 10/05/2022.

**3. The Tender has been floated on e-proc Portal for 13 (Thirteen) Drugs.**

**4.** Total 04 bidders were found to have successfully submitted their bids on the e-proc online system. The submission status of hard copy of the technical bids including the tender fee and Earnest Money Deposit (EMD), till the stipulated time was found as following: -

Sl No.	Name of the Firm	Online submission status of bids on E-Proc	Requisite Tender fee of Rs 10,000/- receipt Status	Requisite Amount of EMD receipt Status	Remarks
1	M/s Bharti Milk Foods Pvt. Ltd.	Ok	Received	Received	Ok
2	M/s Halewood Laboratories Pvt. Ltd.	Ok	Received	Received	Ok
3	M/s Kras Pharmaceuticals Pvt. Ltd.	Ok	Received	Received	Ok
4	M/s Supermax Drugs and Pharmaceuticals Pvt Ltd	Ok	Received	Received	Ok

**5.** The TEC therefore unanimously decided to recommend for technical evaluation of all received 04 (Four) bids by the team of Drug Inspectors deputed at BMSICL.

**6. The item wise bid received status was as follows:**

S.N	Name of the Product with specification	Participating Firms	No. of Bids
1	Oral Glycerol Standard Composition Oral Liquid 1litre	<b>No Bidder Participated</b>	<b>0</b>
2	Glucose Powder Standard Composition [As per FSSAI] Powder 100gm	M/s Bharti MilkFoods Pvt. Ltd. M/s Halewood Laboratories Pvt. Ltd.	2
3	Vitamin E 50mg/ml Drop 30ml	<b>No Bidder Participated</b>	<b>0</b>

	Bottle		
4	Thiamine 100mg Tablet	<b>No Bidder Participated</b>	<b>0</b>
5	Biotin 10mg Tablet	<b>No Bidder Participated</b>	<b>0</b>
6	Carnitine 500mg/5ml Oral Liquid 30ml Bottle	<b>No Bidder Participated</b>	<b>0</b>
7	Riboflavin 5mg Tablet	M/s Kras Pharmaceuticals Pvt. Ltd.	1
8	Midazolam Intra Nasal Spray 0.5mg/Puff Nasal Spray 50 MDI	<b>No Bidder Participated</b>	<b>0</b>
9	Ampicillin 1 gm Injection Vial	M/s Supermax Drugs and Pharmaceuticals Pvt Ltd	1
10	Sodium Valproate 100mg/ml Injection Vial	<b>No Bidder Participated</b>	<b>0</b>
11	Dextrose 25% Injection 25ml Ampoule	<b>No Bidder Participated</b>	<b>0</b>
12	Diazepam Rectal 2mg/2.5ml Liquid 2.5 ml (RDS)	<b>No Bidder Participated</b>	<b>0</b>
13	Diazepam Rectal 5mg/5ml Liquid 5ml (RDS)	<b>No Bidder Participated</b>	<b>0</b>

**7. The summary of Bid received status was as follows:**

1. No Bids received for **10** Drugs.
2. Single Bid received for **02** Drugs.
3. Multiple Bids received for **01** Drug.

**8.** It was therefore unanimously decided by TEC in its meeting dated 11.05.2022 to recommend for Re-tender of Drugs at NIT SN- 1, 3, 4, 5, 6, 8, 10, 11,12 & 13 (**10 Drugs**) due to no bid condition and to evaluate the bids pertaining to only **those 02 drugs** (NIT SN- 7 & 9) for which Single bids have been received as per the Notification of Finance Department, Govt. of Bihar vide Resolution No-7806 Dated - 30-09-2016 (this being a retender) and **01 drugs** (NIT SN- 2) for which multiple bids have been received.

**9.** The Preliminary Evaluation of technical bids of the above-mentioned bidding firms was done by the assigned team including Drug Inspectors deputed at BMSICL. Evaluation sheets were published on the website of BMSICL and Claims/objections were invited vide notice no. 1135 dated 19.05.2022.

**10.** After comparison of the clarification received from the bidders in the light of that notice and close examination of the documents submitted by the bidding firms, the Drug wise technical evaluation findings by TEC in its meeting dated 24.05.2022 were recorded as follows:

S.N	NIT S.N	Name of the Product with specification	Participating Firms	Technical Qualification Status (Qualified/ Disqualified)	Remarks
1	2	Glucose Powder Standard Composition [As per FSSAI] Powder 100gm	M/s Bharti MilkFoods Pvt. Ltd.	Qualified	Ok
			M/s Halewood Laboratories Pvt. Ltd.	Qualified	Ok

2	7	Riboflavin 5mg Tablet	M/s Kras Pharmaceuticals Pvt. Ltd.	Qualified	Ok
3	9	Ampicillin 1 gm Injection Vial	M/s Supermax Drugs and Pharmaceuticals Pvt Ltd	Qualified	Ok

11. As per the above comparative chart all the bidders namely M/s Bharti Milk Foods Pvt. Ltd., M/s Halewood Laboratories Pvt. Ltd., M/s Kras Pharmaceuticals Pvt. Ltd. & M/s Supermax Drugs and Pharmaceuticals Pvt Ltd were found technically qualified as mentioned above.

12. The manufacturing unit of the Two (02) firms namely M/s Kras Pharmaceuticals Pvt. Ltd. & M/s Supermax Drugs and Pharmaceuticals Pvt Ltd were inspected previously and is having valid rate contract with BMSICL or successfully executed rate contract with BMSICL. As the product (Glucose Powder 100gm (As per FSSAI) quoted by the remaining (2) Two firms i.e., M/s Bharti Milk Foods Pvt. Ltd. & M/s Halewood Laboratories Pvt. Ltd. comes under food item and since these products have been identified as the crucial product for the management of AES according to SOP-2021 and in view of increase in reported cases of AES these products are urgently required, hence it was therefore unanimously decided by TEC in its meeting dated 24.05.2022 to recommend for factory inspection of remaining (2) Two firms i.e., M/s Bharti Milk Foods Pvt. Ltd. & M/s Halewood Laboratories Pvt. Ltd., later on if required, as per Clause 15 (a) of the bid document which reads as “**Inspections of the production and related facilities of bidders/ suppliers will be at the discretion of the Tender Inviting Authority. Such inspection may be at any stage before or after acceptance of the Bid or Award of Contract**”. It was therefore unanimously decided in that TEC meeting for opening of the financial bids of the technically qualified bidders on e -proc Portal.

13. The factory inspection of (2) Two firms i.e., M/s Bharti Milk Foods Pvt. Ltd. & M/s Halewood Laboratories Pvt. Ltd. has been conducted by the team of Drug Inspectors. After perusal of the Factory Inspection report, both firms were found technically qualified. Accordingly, the financial bids of technically qualified bidders were opened today on e-proc Portal, in which the following result has been observed: -

S.N	NIT S.N	Name of the Product with specification	Participating Firms	Quoted Rate for Each Sachet/ Tablet/Ampoule (Excluding GST)	Bid Ranking
1	2	Glucose Powder Standard Composition [As per FSSAI] Powder 100gm	M/s Halewood Laboratories Pvt. Ltd.	10.69	L1
			M/s Bharti MilkFoods Pvt. Ltd.	11.48	L2
2	7	Riboflavin 5mg Tablet	M/s Kras Pharmaceuticals Pvt. Ltd.	0.24	NA
3	9	Ampicillin 1 gm Injection Vial	M/s Supermax Drugs and Pharmaceuticals Pvt Ltd	11.97	NA

14. On perusal of the above said result (downloaded copy annexed as Annexure-A to this proceeding), it was unanimously recommended to invite the consent from the L2 bidder (**M/s Bharti MilkFoods Pvt. Ltd.**) to accept the L1 declared rate for the product at NIT S.No.2 (Glucose Powder 100gm) and to issue the LoI accordingly as per provisions of splitting contained in the tender clause 19 (a) of the Tender Document.

15. Since this tender being a retender, hence it was unanimously decided to ask the bidders for the two drugs i.e. **Riboflavin 5mg Tablet and Ampicillin 1 gm Injection Vial** under single bid condition to justify their quoted price vis-à-vis other procurement agencies across the country and to find out the prevailing market rate (Authorized dealer price, Carrying & Forwarding Agent Price & Sales depot price) of the corresponding manufacturer through the State Drug Regulatory Authority, so that the matter could be decided by the board of Directors of BMSICL as per the provisions contained in the notification no. 7806 dated 30/09/2016 of Finance Department, Govt. of Bihar.

16. The meeting thus concluded with a vote of thanks.

Sd/-  
(**Ramendra Kumar**)  
GM (Finance), BMSICL, Patna

Sd/-  
(**Dr. Vidyapati Choudhary**)  
Principal PMCH, Patna

Sd/-  
(**Sudhir Kumar**)  
GM (Procurement), BMSICL, Patna

Sd/-  
(**Rajani Kant**)  
CGM (Supply Chain), BMSICL, Patna.

Sd/-  
(**Dr. Maheshwar Prasad Gupta**)  
Director in Chief, Health Dept., Govt. of Bihar.

Sd/-  
(**Shrawan Kumar**)  
Internal Financial Advisor, Health Dept., Govt. of Bihar.

Sd/-  
(**Dinesh Kumar**)  
Managing Director, BMSICL.